文章：

肠道微生物组在非霍奇金淋巴瘤中的作用：聚焦弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、皮肤T细胞淋巴瘤及NK/T细胞淋巴瘤

The Role of the Gut Microbiome in Non-Hodgkin Lymphoma (NHL): A Focus on Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Cutaneous T-Cell Lymphoma, and NK/T-Cell Lymphoma

原文发布日期：20 May 2025

DOI: 10.3390/cancers17101709

类型: Article

开放获取: 是

英文摘要：

Non-Hodgkin lymphomas (NHLs) encompass a diverse group of neoplasms arising from the clonal proliferation of B-cell progenitors, T-cell progenitors, mature B-cells, mature T-cells, and natural killer (NK) cells. These malignancies account for over 90% of lymphoid neoplasms. The link between the gut microbiome and neoplasms has been extensively studied in recent years. Growing evidence suggests that the gut microbiome may be involved not only in the development of the disease, but also in modulating the efficacy of implemented therapies. In this review, we summarize the current knowledge on the potential involvement of the gut microbiome in the development of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, and NK/T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL). Moreover, we discuss the relationship between gut microbiome changes before and after treatment and their association with treatment outcomes, focusing on chemotherapy and CAR T-cell therapy.

摘要翻译： 

非霍奇金淋巴瘤（NHL）是一组异质性肿瘤，源于B细胞前体、T细胞前体、成熟B细胞、成熟T细胞及自然杀伤（NK）细胞的克隆性增殖。这类恶性肿瘤占所有淋巴组织肿瘤的90%以上。近年来，肠道微生物群与肿瘤之间的关联已得到广泛研究。越来越多的证据表明，肠道微生物群不仅可能参与疾病的发生发展，还可能影响现有治疗方法的疗效。本文综述了当前关于肠道微生物群在弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）、黏膜相关淋巴组织（MALT）淋巴瘤以及NK/T细胞淋巴瘤（包括皮肤T细胞淋巴瘤[CTCL]）发生发展中潜在作用的研究进展。此外，我们重点探讨了化疗和CAR-T细胞治疗前后肠道微生物群的变化及其与治疗结局的关联。

原文链接：

The Role of the Gut Microbiome in Non-Hodgkin Lymphoma (NHL): A Focus on Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Cutaneous T-Cell Lymphoma, and NK/T-Cell Lymphoma